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Dipeptidyl Peptidase-4 Inhibitor-
Associated Bullous Pemphigoid
Ágnes Kinyó
Abstract
Bullous pemphigoid (BP) is the most common type of autoimmune bullous 
diseases; drug-induced bullous pemphigoid is a rare variant of it. In the last decade, 
there is an increasing prevalence of BP, especially dipeptidyl peptidase-4 inhibitor-
associated BP (DPP-4i-BP), with the higher prevalence of BP in diabetic patients. 
Recently, several clinical phenotypes of BP were detected, but there is a tendency 
in BP cases related to DPP-4 inhibitors to show an atypical noninflammatory form 
with less distributed skin symptoms, mild erythema, decreased eosinophilic infil-
tration in the periblister area, and normal or slightly elevated peripheral eosinophil 
count. Anti-NC16A BP180 autoantibodies are less frequently detected by ELISA, 
but they response to other epitopes of BP180. Clinical outcome is similar such as in 
classical non-DPP-4 BP patients, regardless of withdrawal of DPP-4 inhibitors.
Keywords: bullous pemphigoid, noninflammatory, dipeptidyl peptidase-4 inhibitor, 
gliptins, eosinophil
1. Introduction
Bullous pemphigoid (BP) is a rare autoimmune blistering disease of elderly 
patients, but in the last decades, it shows increasing incidence [1–8]. Higher preva-
lence of BP may be according to the increasing global life expectancy of the popula-
tion, increasing incidence of predisposing neurological diseases, growing numbers 
of provoking drugs, and improving awareness of newly recognized atypical clinical 
phenotypes and better diagnostic methods [1]. The role of culprit drugs such as 
neuroleptics, diuretics, and antidiabetics is reported in several studies [1, 2, 9]. BP 
is typically present in elderly with a higher predominance in female patients [4, 7]. 
The classical clinical features of BP are generalized bullous skin eruptions with sur-
rounding erythema and itching; peripheral eosinophilia is also common. Mucosal 
involvement was observed in 10–30% of patients [2]. Atypical clinical variants may 
be present up to 20% in BP, including the more common prurigo-like or urticarial 
type, eczema-like type, dyshidrosiform type, erosive type, and erythema annulare 
centrifugum-like phenotype [1, 7]. The diagnosis is based on the histological 
findings, including direct and indirect immunofluorescence microscopy and 
anti-BP180/BP230 enzyme-linked immunosorbent assays (ELISA) [2]. The gold 
standard for the treatment of the disease according to guidelines is corticosteroid, 
in topical or systemic administration and in severe cases with adjuvant immuno-
suppressive medications, such as azathioprine, methotrexate, or mycophenolate 
mofetil [2]. In the case of drug-induced BP, the most important therapeutic step is 
the withdrawal of the culprit drug [9].
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2. Bullous pemphigoid and diabetes
BP is a chronic, relapsing disease in patients with several comorbidities and 
significant morbidity. Investigating the prevalence of diabetes mellitus (DM) in BP, 
a higher frequency of DM has been found in the last decade [10, 11]. In accordance 
to several case reports [12–18], case series, case-control studies, pharmacovigilance 
reports, and retrospective investigations [19–37], the growing number of DM in BP 
patients is in association with the increasing use of an antidiabetic drug, the dipep-
tidyl peptidase-4 inhibitor (DPP-4i). DPP-4i, also called gliptins, was approved in 
2006 to treat type 2 DM. Sitagliptin, vildagliptin, linagliptin, saxagliptin, and alo-
gliptin have been approved by FDA or EMA; anagliptin, trelagliptin, omarigliptin, 
and teneligliptin have approval only in Japan. Gliptins are used in monotherapy or 
in combination with metformin. However, there is a clear evidence of provoking 
role of DPP-4 inhibitors in BP; the pathomechanism of it is still not understood.
3. Demographics of DPP-4 inhibitor-related BP
DPP-4 inhibitor intake was associated with a threefold increased risk for BP [27, 31, 38].  
According to the former investigations [14, 23, 26, 27, 29, 31, 38, 39], vildagliptin has 
the strongest association with BP; the risk was tenfold (ranged between 7.23 and 11.8) 
in a systemic review and meta-analysis by Kridin et al. [38]. A higher, sixfold risk 
was also observed with linagliptin [27, 38]. Higher risk of DPP-4i-BP was also found 
with sitagliptin by Lee et al. [40], and they also found in a larger sample size (patients 
with DPP-4i-BP n = 260) that the risks associated with specific DPP-4 inhibitors were 
lower than the previous studies [27, 38], 1.81 for vildagliptin, 1.64 for linagliptin, and 
1.7 for sitagliptin. However, a significant association was detected with vildagliptin, 
linagliptin, and sitagliptin in age- and sex-matched controlled population; the associa-
tion with saxagliptin in BP was not significant [27, 31]. Saxagliptin, anagliptin- and 
alogliptin-induced BP were presented only in a few sporadic cases [29, 31, 32, 40, 41]. 
DPP-4 inhibitors are often given in combination with metformin; the two recent pub-
lications reported that the association of BP and gliptins is independent of metformin 
exposure [27, 30]. Despite the BP is more common in females, a multicenter investiga-
tion and EudraVigilance data showed that DPP-4 inhibitor-associated BP tends to be 
more common in men [14, 23], similarly to Kridin et al. [27] and Lee et al. [40] and 
in contrast to Varpuluoma et al., who found a higher risk for BP in women taking 
DPP-4 inhibitors [30]. The mean age of DPP-4i-related BP patients ranged between 
76.6 and 79.1 years [23, 27, 39]. Kridin et al. presented the strongest association in 
patients younger than 70 years [27], while Benzaquen et al. found stronger association 
in patients older than 80 years [23], while Lee et al. observed 1.76-fold risk in patients 
younger than 75 years and 1.5-fold risk in patients older than 75 years [40]. The mean 
latency period between the initiation of gliptin and the appearance of BP is ranging 
from 6 to 26.4 months  
[23, 27, 29, 30, 33]. That means DPP-4 inhibitors can be suspected in the pathogenesis 
of BP if the drug has been initiated at least 6 months, but it also has to be considered if 
the drug intake last for more than 2 years prior to the onset of BP.
4. Clinical features of DPP-4 inhibitors-related noninflammatory BP
The classical clinical picture of BP is generalized as bullous skin lesions, tense blis-
ters with severe urticarial erythema. Recent publications characterized a noninflam-
matory form of BP with limited distribution, smaller blisters, and scant erythema 
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(Figures 1 and 2) [37, 42, 43]. These noninflammatory phenotypes do not react with 
the NC16A domain of BP, show better clinical outcome, and has a higher prevalence 
in DPP-4 inhibitor taking patients [22, 32, 34–37, 42, 43]. Noninflammatory BP can 
Figure 1. 
DPP-4i-related bullous pemphigoid. Mild skin involvement localized to the upper part of the trunk with small 
blisters and erosions without erythema in a male patient.
Figure 2. 
DPP-4i-related bullous pemphigoid in a female patient with small, round erosions without 
erythema on the upper extremities.
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also be found in non-DPP-4-related cases but in a significantly lower manner. Higher 
frequency of mucosal involvement was reported in gliptin-associated BP in two 
studies (Kridin et al., 22.2%, n = 36, and Chijiwa et al., 78%, n = 9) [27, 33], but this 
observation was not supported by Plaquevent (n = 108) [31]. Interestingly, in gliptin-
associated mucous membrane pemphigoid (MMP) there is a significantly lower buc-
cal and more common cutaneous involvement [44]. Previous studies demonstrated 
that eosinophil count is in correlation with the severity of BP [45–47] and with BPDAI 
score [46]. Comparing the Bullous Pemphigoid Disease Area Index (BPDAI) [48], 
BPDAI scores for urticaria/erythema (U/E) were significantly lower in noninflam-
matory phenotypes [33, 36, 42, 43], and lower BPDAI U/E was in correlation with 
decreased eosinophil count in the perilesional skin [33, 42]. Significantly decreased 
peripheral eosinophil count was detected in patients of Kridin et al. [27].
5. Immunological characterization of DPP-4 inhibitor-related BP
In BP, there are two targets for autoantibodies, the hemidesmosomal BP180 
and BP230 and the juxtamembranous extracellular non-collagenous 16A 
(NC16A), both of them can be easily detected by commercially available ELISA 
tests [2, 49, 50]. The domain of BP180 (also called COL17) is a major target 
epitope in 80–90% of cases [49]. In several investigations, noninflammatory BP 
patients did not show reactivity against the NC16A domain of BP180, but they 
were positive for full-length BP180 and its ectodomain midportion with ELISA 
[34, 36, 42]. The midportion of BP180 is more likely to be recognized than the 
NC16A domain in DPP-4i-associated noninflammatory BP patients; they are pre-
sented with localized symptoms and mild erythema [32, 35, 36, 42, 51]. Although 
there was a positive reaction to anti-NC16A in DPP-4i-BP cases, but they were 
mainly presented with prominent erythema and inflammation, concurring with 
classical phenotype of BP [31, 35, 42]. Kawaguchi et al. showed that the rate of 
ELISA positivity and antibody titers for anti-BP180 NC16A was significantly 
lower in DPP-4i-BP than the non-DPP-4 group [22], and this lower titer was also 
observed by García-Díez et al. [52]. Kawaguchi has also emphasized that patients 
with DPP-4i-BP tended to have noninflammatory phenotype of BP and presented 
with negative ELISA for BP180 NC16A domain [22]. Some studies reported 
noninflammatory DPP-4-induced BP patients who were negative for anti-NC16A 
domain initially but responded to the full-length BP180 and became positive for 
NC16A during the course of the disease. This epitope spreading was observed in 
several cases, after the prolonged use of DPP-4 inhibitors after the onset of BP  
[17, 37, 52]. Other investigations also demonstrated that multiple epitopes of 
BP180 are targeted in DPP-4i-BP (midportion, C terminus, and LAD1) [35, 52], 
and it may suggest that epitope spreading is more common in DPP-4i-BP than 
in classical BP cases [35]. García-Díez et al. suggested the major role of the 
midportion of BP180 in DPP-4i-BP, while other BP180 regions are involved later 
by epitope spreading [52]. Indirect IF positivity was also detected in DPP-4i-BP 
patients [13, 27, 34], and anti-BP230 autoantibodies were present [34, 35], but the 
sensitivity of the test was only 38%, which is lower than usually reported [51].
6. Clinical outcome
Based on several investigations, withdrawal of the DPP-4 inhibitors was the first 
therapeutic step in most cases in the treatment of the disease [23, 34]. Regarding 
to these data, discontinuation of DPP-4i treatment seems to have a favorable 
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impact on the clinical outcome of BP [23, 27, 34], but Plaquevent et al. have found 
that there is no difference in outcome in patients who have further got the gliptin 
treatment after the diagnosis of BP [31]. Regardless of DPP-4 inhibitor withdrawal, 
standard treatment protocol was applied in most cases, topical potent corticosteroid 
treatment in localized form and gold standard systemic corticosteroid treatment 
with adjuvant immunosuppressive therapy, such as azathioprine, mycophenolate 
mofetil, or methotrexate in severe cases [27, 31]. Relapse rates were similar in DPP-
4i-BP patients such it was previously reported [31].
7. Conclusions
Dipeptidyl peptidase-4 inhibitors (also called gliptins) are widely used drug 
in the treatment of type 2 diabetes mellitus. There is an increased risk of BP in 
patients during DPP-4 inhibitor treatment. The exact pathomechanism of DPP-
4i-associated BP is still unclear. Dipeptidyl peptidase 4 (also called CD26) is a 
110 kDa transmembrane glycoprotein, which is expressed on the surface of several 
cells, such as T cells [53, 54]. DPP-4 has antihyperglycemic effect and enzymatic 
activity; it plays a major role in glucose metabolism by blocking incretin [54]. 
DPP-4 is a plasminogen receptor that activates plasminogen resulted in plasmin 
formation [55, 56]. Plasmin, a serine protease, which has a high level in lesional 
skin and in blister fluid in BP [57], cleaves BP180 within the NC16A domain [58]. 
Cleavage of BP180 in the NC16A region can induce neoepitopes with altered anti-
genicities [42, 59]. The antifibrotic effect of DPP-4 inhibitors in the skin also sup-
ports the role of DPP-4 in collagen metabolism [56]. DPP-4 is involved in immune 
cell activation, and its inhibition can modify the immune response, which may 
increase the activation of eosinophil recruitment into the dermis, which is consid-
ered to be essential in blister formation in BP [60]. In contrary to these findings, 
in patients with gliptin-associated noninflammatory BP, both peripheral and 
perilesional skin eosinophil counts are significantly lower than in classical BP 
[27, 33], so the exact pathognostic role of eosinophils in DPP-4-related BP needs 
further investigations. It is also not elucidated why vildagliptin has the strongest 
association with BP, but it is known that vildagliptin has the lowest selectivity 
among gliptins with strong inhibition of DDP8 and DPP9 isozymes [22, 61]. 
Some results suggest that DPP-4 inhibitor has immunomodifier effect mainly in 
Table 1. 
Comparison of clinical features in DPP-4i-related and classical type bullous pemphigoid.
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
genetically susceptible individuals, and they have detected that HLA-DQB1*03:01 
allele has higher prevalence in DPP-4i-BP patients [22, 62].
In conclusion, DPP-4 inhibitor-related BP tends to be presented with noninflam-
matory phenotype of BP, with limited extension, smaller blisters, scant perilesional 
erythema and eosinophilic infiltration, and normal or slightly elevated peripheral 
eosinophil count (Table 1). Anti-NC16A BP180 positivity is less common, and ELISA 
titers are slightly elevated, similarly to anti-BP230, but positivity for full-length BP180 
or other epitopes of BP180 may be detected. Response to therapy is similar such as in 
classical non-DPP-4i-BP patients, regardless of withdrawal of DPP-4 inhibitors.
Conflict of interest
There is no conflict of interest.
Acronyms and abbreviations
BP  bullous pemphigoid
BPDAI bullous pemphigoid disease area index
COL17 collagen XVII
DM  diabetes mellitus
DPP-4 dipeptidyl peptidase-4
DPP-4i-BP dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid
ELISA enzyme-linked immunosorbent assays
EMA European Medicines Agency
FDA  Food and Drug Administration
NC16A non-collagenous 16A
MMP mucous membrane pemphigoid
BPDAI BP disease area index
Author details
Ágnes Kinyó
Department of Dermatology, Venereology and Oncodermatology, University of 
Pécs, Pécs, Hungary
*Address all correspondence to: kinyo.agnes@pte.hu
7Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
DOI: http://dx.doi.org/10.5772/intechopen.84933
References
[1] Kridin K, Ludwig RJ. The 
growing incidence of bullous 
Pemphigoid: Overview and potential 
explanations. Frontiers in Medicine 
(Lausanne). 2018;5:220. DOI: 10.3389/
fmed.2018.00220
[2] Bernard P, Antonicelli F. Bullous 
pemphigoid: A review of its diagnosis, 
associations and treatment. American 
Journal of Clinical Dermatology. 
2017;18:513-528. DOI: 10.1007/
s40257-017-0264-2
[3] Schmidt E, Spindler V, Eming R, 
Amagai M, Antonicelli F, Baines JF, 
et al. Meeting report of the pathogenesis 
of pemphigus and Pemphigoid meeting 
in Munich, September 2016. The 
Journal of Investigative Dermatology. 
2017;137:1199-1203. DOI: 10.1016/j.
jid.2017.01.028
[4] Langan SM, Smeeth L, Hubbard R, 
Fleming KM, Smith CJP, West J.  
Bullous pemphigoid and pemphigus 
vulgaris—Incidence and mortality in 
the UK: Population based cohort study. 
BMJ. 2008;337:160-163. DOI: 10.1136/
bmj.a180
[5] Hübner F, Recke A, Zillikens D, 
Linder R, Schmidt E. Prevalence and 
age distribution of pemphigus and 
pemphigoid diseases in Germany. The 
Journal of Investigative Dermatology. 
2016;136:2495-2498. DOI: 10.1016/j.
jid.2016.07.013
[6] Bernard P, Vaillant L, Labeille B, 
Bedane C, Arbeille B, Denoeux JP, 
et al. Incidence and distribution of 
subepidermal autoimmune bullous skin 
diseases in three French regions. Bullous 
diseases French study group. Archives of 
Dermatology. 1995;131:48-52
[7] Joly P, Baricault S, Sparsa A, 
Bernard P, Bédane C, Duvert-Lehembre S, 
et al. Incidence and mortality of 
bullous pemphigoid in France. The 
Journal of Investigative Dermatology. 
2012;132:1998-2004. DOI: 10.1038/
jid.2012.35
[8] Försti AK, Jokelainen J, Timonen M,  
Tasanen K. Increasing incidence of 
bullous pemphigoid in Northern 
Finland: A retrospective database study 
in Oulu University Hospital. The British 
Journal of Dermatology. 2014;171: 
1223-1226. DOI: 10.1111/bjd.13189
[9] Stavropoulos PG, Soura E, Antoniou C.  
Drug-induced pemphigoid: A review 
of the literature. Journal of the 
European Academy of Dermatology and 
Venereology. 2014;28:1133-1140. DOI: 
10.1111/jdv.12366
[10] Fania L, Di Zenzo G, Didona B, 
Pilla MA, Sobrino L, Panebianco A, 
et al. Increased prevalence of diabetes 
mellitus in bullous pemphigoid patients 
during the last decade. Journal of the 
European Academy of Dermatology and 
Venereology. 2018;32:e153-e154. DOI: 
10.1111/jdv.14649
[11] Gravani A, Gaitanis G, Tsironi T, 
Tigas S, Bassukas ID. Changing 
prevalence of diabetes mellitus in 
bullous pemphigoid: It is the dipeptidyl 
peptidase-4 inhibitors. Journal of the 
European Academy of Dermatology and 
Venereology. 2018;32:e438-e439. DOI: 
10.1111/jdv.14957
[12] Aouidad I, Fite C, Marinho E, 
Deschamps L, Crickx B, Descamps V. A 
case report of bullous pemphigoid 
induced by dipeptidyl peptidase-4 
inhibitors. JAMA Dermatology. 
2013;149:243-245. DOI: 10.1001/
jamadermatol.2013.1073
[13] Attaway A, Mersfelder TL, 
Vaishnav S, Baker JK. Bullous 
pemphigoid associated with dipeptidyl 
peptidase IV inhibitors. A case 
report and review of literature. 
Journal of Dermatological Case 
Metabolic Disorders
8
Reports. 2014;8:24-28. DOI: 10.3315/
jdcr.2014.1166
[14] García M, Aranburu MA, 
Palacios-Zabalza I, Lertxundi U, 
Aguirre C. Dipeptidyl peptidase-IV 
inhibitors induced bullous pemphigoid: 
A case report and analysis of 
cases reported in the European 
pharmacovigilance database. Journal of 
Clinical Pharmacy and Therapeutics. 
2016;41:368-370. DOI: 10.1111/jcpt.12397
[15] Harada M, Yoneda A, Haruyama S, 
Yabuki K, Honma Y, Hiura M, et al. 
Bullous Pemphigoid associated with 
the dipeptidyl peptidase-4 inhibitor 
sitagliptin in a patient with liver 
cirrhosis complicated with rapidly 
progressive hepatocellular carcinoma. 
Internal Medicine. 2017;56:2471-2474. 
DOI: 10.2169/internalmedicine.8703-16
[16] Maki N, Nishie W, Takazawa M, 
Kakurai M, Yamada T, Umemoto N, 
et al. Dipeptidyl peptidase-4 inhibitor-
associated bullous pemphigoid in 
a patient with acquired reactive 
perforating collagenosis. The Journal of 
Dermatology. 2018;45:600-602. DOI: 
10.1111/1346-8138.14254
[17] Takama H, Yoshida M, Izumi K, 
Yanagishita T, Muto J, Ohshima Y, 
et al. Dipeptidyl peptidase-4 inhibitor-
associated bullous pemphigoid: 
Recurrence with epitope spreading. Acta 
Dermato-Venereologica. 2018;98: 
983-984. DOI: 10.2340/00015555-3010
[18] Oya K, Fujii M, Taguchi S, Nishie W, 
Izumi K, Shimizu H. Localized bullous 
pemphigoid associated with dipeptidyl 
peptidase-4 inhibitor treatment. European 
Journal of Dermatology. 2018;28:250-251. 
DOI: 10.1684/ejd.2018.3230
[19] Pasmatzi E, Monastirli A, Habeos J, 
Georgiou S, Tsambaos D. Dipeptidyl 
peptidase-4 inhibitors cause bullous 
pemphigoid in diabetic patients: 
Report of two cases. Diabetes Care. 
2011;34:e133. DOI: 10.2337/dc11-0804
[20] Mendonça FM, Martín-Gutierrez FJ, 
Ríos-Martín JJ, Camacho-Martinez F.  
Three cases of bullous pemphigoid 
associated with dipeptidyl peptidase-4 
inhibitors—One due to Linagliptin. 
Dermatology. 2016;232:249-253. DOI: 
10.1159/000443330
[21] Haber R, Fayad AM, Stephan F, 
Obeid G, Tomb R. Bullous pemphigoid 
associated with linagliptin treatment. 
JAMA Dermatology. 2016;152:224-226. 
DOI: 10.1001/jamadermatol.2015.2939
[22] Kawaguchi Y, Shimauchi R, 
Nishibori N, Kawashima K, Oshitani S, 
Fujiya A, et al. Dipeptidyl peptidase-4 
inhibitors-associated bullous 
pemphigoid: A retrospective study of 
168 pemphigoid and 9,304 diabetes 
mellitus patients. Journal of Diabetes 
Investigation. 2018. DOI: 10.1111/
jdi.12877. [Epub ahead of print]
[23] Benzaquen M, Borradori L, Berbis P, 
Cazzaniga S, Valero R, Richard MA, 
et al. Dipeptidyl peptidase IV inhibitors, 
a risk factor for bullous pemphigoid: 
Retrospective multicenter case-control 
study from France and Switzerland. 
Journal of the American Academy of 
Dermatology. 2018;78:1090-1096. DOI: 
10.1016/j.jaad.2017.12.038
[24] Béné J, Jacobsoone A, Coupe P, 
Auffret M, Babai S, Hillaire-Buys D, 
et al. Bullous pemphigoid induced by 
vildagliptin: A report of three cases. 
Fundamental & Clinical Pharmacology. 
2015;29:112-114. DOI: 10.1111/bjd.14601
[25] Skandalis K, Spirova M, Gaitanis G, 
Tsartsarakis A, Bassukas ID. Drug-
induced bullous pemphigoid in 
diabetes mellitus patients receiving 
dipeptidyl peptidase-IV inhibitors plus 
metformin. Journal of the European 
Academy of Dermatology and 
Venereology. 2012;26:249-253. DOI: 
10.1111/j.1468-3083.2011.04062.x
[26] Schaffer C, Buclin T, Jornayvaz FR, 
Cazzaniga S, Borradori L, Gilliet M, 
9Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
DOI: http://dx.doi.org/10.5772/intechopen.84933
et al. Use of Dipeptidyl-peptidase IV 
inhibitors and bullous pemphigoid. 
Dermatology. 2017;233:401-403. DOI: 
10.1159/000480498
[27] Kridin K, Bergman R. Association 
of bullous pemphigoid with dipeptidyl-
peptidase 4 inhibitors in patients 
with diabetes: Estimating the risk of 
the new agents and characterizing 
the patients. JAMA Dermatology. 
2018;154:1152-1158. DOI: 10.1001/
jamadermatol.2018.2352
[28] Arai M, Shirakawa J, Konishi H, 
Sagawa N, Terauchi Y. Bullous 
pemphigoid and dipeptidyl peptidase 4 
inhibitors: A disproportionality analysis 
based on the Japanese adverse drug 
event report database. Diabetes Care. 
2018;41:e130-e132. DOI: 10.2337/dc18-0210
[29] Béné J, Moulis G, Bennani I, 
Auffret M, Coupe P, Babai S, et al. 
French Association of Regional 
PharmacoVigilance Centres: Bullous 
pemphigoid and dipeptidyl peptidase 
IV inhibitors: A case-noncase study in 
the French Pharmacovigilance database. 
The British Journal of Dermatology. 
2016;175:296-301. DOI: 10.1111/fcp.12083
[30] Varpuluoma O, Försti AK, 
Jokelainen J, Turpeinen M, Timonen M, 
Tasanen K, et al. Oral diabetes 
medications other than dipeptidyl 
peptidase 4 inhibitors are not associated 
with bullous pemphigoid: A Finnish 
nationwide case-control study. 
Journal of the American Academy of 
Dermatology. 2018;79:1034-1038. DOI: 
10.1016/j.jaad.2018.05.030
[31] Plaquevent M, Tétart F, Fardet L, 
et al. Higher frequency of dipeptidyl 
peptidase IV inhibitor intake in 
bullous pemphigoid patients than in 
the French general population. The 
Journal of Investigative Dermatology. 
2018;18:32923-3. DOI: 10.1016/j.jid.2018
[32] Yoshiji S, Murakami T, Harashima 
SI, Ko R, Kashima R, Yabe D, et al. 
Bullous pemphigoid associated with 
dipeptidyl peptidase-4 inhibitors: A 
report of five cases. Journal of Diabetes 
Investigation. 2018;9:445-447. DOI: 
10.1111/jdi.12695
[33] Chijiwa C, Takeoka S, Kamata M, 
Tateishi M, Fukaya S, Hayashi K,  
et al. Decrease in eosinophils infiltrating 
into the skin of patients with dipeptidyl 
peptidase-4 inhibitor-related 
bullous pemphigoid. The Journal of 
Dermatology. 2018;45:596-599. DOI: 
10.1111/1346-8138.14245
[34] García-Díez I, Ivars-Lleó M, López-
Aventín D, Ishii N, Hashimoto T, Iranzo P, 
et al. Bullous pemphigoid induced by 
dipeptidyl peptidase-4 inhibitors. Eight 
cases with clinical and immunological 
characterization. International Journal 
of Dermatology. 2018;57:810-816. DOI: 
10.1111/ijd.14005
[35] Fania L, Salemme A, Provini A, 
Pagnanelli G, Collina MC, Abeni D, 
et al. Detection and characterization 
of IgG, IgE, and IgA autoantibodies 
in patients with bullous pemphigoid 
associated with dipeptidyl peptidase-4 
inhibitors. Journal of the American 
Academy of Dermatology. 2018;78: 
592-595. DOI: 10.1016/j.
jaad.2017.09.051
[36] Horikawa H, Kurihara Y, Funakoshi T, 
Umegaki-Arao N, Takahashi H, Kubo A, 
et al. Unique clinical and serological 
features of bullous pemphigoid 
associated with dipeptidyl peptidase-4 
inhibitors. The British Journal of 
Dermatology. 2018;178:1462-1463. DOI: 
10.1111/bjd.16479
[37] Mai Y, Nishie W, Izumi K, 
Yoshimoto N, Morita Y, Watanabe 
M, et al. Detection of anti-BP180 
NC16A autoantibodies after the onset 
of dipeptidyl peptidase-IV inhibitor-
associated bullous pemphigoid: A report 
of three patients. The British Journal of 
Dermatology. 2018;179:790-791. DOI: 
10.1111/bjd.16656
Metabolic Disorders
10
[38] Kridin K, Cohen AD. Dipeptidyl-
peptidase IV inhibitor-associated 
bullous pemphigoid: A systematic 
review and meta-analysis. J Am Acad 
Dermatol. 2018;18:32660-32664. DOI: 
10.1016/j.jaad.2018.09.048
[39] Varpuluoma O, Försti AK, 
Jokelainen J, Turpeinen M, Timonen M, 
Huilaja L, et al. Vildagliptin 
significantly increases the risk of 
bullous pemphigoid: A Finnish 
Nationwide registry study. The 
Journal of Investigative Dermatology. 
2018;138:1659-1661. DOI: 10.1016/j.
jid.2018.01.027
[40] Lee SG, Lee HJ, Yoon MS, Kim DH.  
Association of dipeptidyl peptidase 
4 inhibitor use with risk of bullous 
pemphigoid in patients with diabetes. 
JAMA Dermatology. 2019;155:172-177. 
DOI: 10.1001/jamadermatol.2018.4556
[41] Oya K, Fujii M, Taguchi S, Nishie W, 
Izumi K, Shimizu H.  
Bullous pemphigoid following 
the replacement of vildagliptin 
with anagliptin. The Journal of 
Dermatology. 2017;44:e238-e239. DOI: 
10.1111/1346-8138.13941
[42] Izumi K, Nishie W, Mai Y, Wada M, 
Natsuga K, Ujiie H, et al. Autoantibody 
profile differentiates between 
inflammatory and noninflammatory 
bullous Pemphigoid. The Journal 
of Investigative Dermatology. 
2016;136:2201-2210. DOI: 10.1016/j.
jid.2016.06.622
[43] Nakama K, Koga H, Ishii N, Ohata C, 
Hashimoto T, Nakama T. Clinical and 
immunological profiles of 14 patients 
with bullous Pemphigoid without 
IgG autoantibodies to the BP180 
NC16A domain. JAMA Dermatology. 
2018;154:347-350. DOI: 10.1001/
jamadermatol.2017.5465
[44] Gaudin O, Seta V, Alexandre M, 
Bohelay G, Aucouturier F, 
Mignot-Grootenboer S, et al. Gliptin 
accountability in mucous membrane 
Pemphigoid induction in 24 out of 313 
patients. Frontiers in Immunology. 
2018;9:1030. DOI: 10.3389/
fimmu.2018.01030
[45] Bernard P, Venot J, Constant F, 
Bonnetblanc JM. Blood eosinophilia as a 
severity marker for bullous pemphigoid. 
Journal of the American Academy of 
Dermatology. 1987;16:879-881
[46] Messingham KN, Holahan HM, 
Frydman AS, Fullenkamp C, Srikantha R, 
Fairley JA. Human eosinophils express 
the high affinity IgE receptor, FcεRI, 
in bullous pemphigoid. PLoS One. 
2014;9:e107725. DOI: 10.1371/journal.
pone.0107725
[47] Kridin K. Peripheral eosinophilia 
in bullous pemphigoid: Prevalence and 
influence on the clinical manifestation. 
The British Journal of Dermatology. 
2018;179:1141-1147. DOI: 10.1111/
bjd.16679
[48] Murrell DF, Daniel BS, Joly P, 
Borradori L, Amagai M, Hashimoto 
T, et al. Definitions and outcome 
measures for bullous pemphigoid: 
Recommendations by an international 
panel of experts. Journal of the 
American Academy of Dermatology 
2012:66:479-485. DOI: 10.1016/j.
jaad.2011.06.032
[49] Schmidt E, Zillikens D. Pemphigoid 
diseases. Lancet. 2013;381(9863): 
320-332. DOI: 10.1016/
S0140-6736(12)61140-4
[50] Sárdy M, Kostaki D, Varga R, Peris K, 
Ruzicka T. Comparative study of direct 
and indirect immunofluorescence and 
of bullous pemphigoid 180 and 230 
enzyme-linked immunosorbent assays 
for diagnosis of bullous pemphigoid. 
Journal of the American Academy of 
Dermatology. 2013;69:748-753. DOI: 
10.1016/j.jaad.2013.07.009
11
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
DOI: http://dx.doi.org/10.5772/intechopen.84933
[51] Sakai A, Shimomura Y, Ansai O, 
et al. Linagliptin-associated bullous 
pemphigoid that was most likely 
caused by IgG autoantibodies against 
the midportion of BP180. The British 
Journal of Dermatology. 2017;176: 
541-543. DOI: 10.1111/bjd.15111
[52] García-Díez I, España A, Iranzo P.  
Epitope spreading phenomena in 
dipeptidyl peptidase-4 inhibitor-
associated bullous pemphigoid. The 
British Journal of Dermatology. 2019. 
DOI: 10.1111/bjd.17690. [Epub ahead of 
print]
[53] Klemann C, Wagner L, Stephan M,  
von Hörsten S. Cut to the chase: A 
review of CD26/dipeptidyl peptidase-4's 
(DPP4) entanglement in the immune 
system. Clinical and Experimental 
Immunology. 2016;185:1-21. DOI: 
10.1111/cei.12781
[54] Röhrborn D, Wronkowitz N, 
Eckel J. DPP4 in Diabetes. Frontiers in 
Immunology. 2015;6:386. DOI: 10.3389/
fimmu.2015.00386
[55] Gonzalez-Gronow M, Kaczowka S, 
Gawdi G, Pizzo SV. Dipeptidyl 
peptidase IV (DPP IV/CD26) is a cell-
surface plasminogen receptor. Frontiers 
in Bioscience. 2008;13:1610-1618
[56] Thielitz A, Ansorge S, Bank U, 
Tager M, Wrenger S, Gollnick H, et al. 
The ectopeptidases dipeptidyl peptidase 
IV (DP IV) and aminopeptidase N 
(APN) and their related enzymes as 
possible targets in the treatment of 
skin diseases. Frontiers in Bioscience. 
2008;13:2364-2375
[57] Schmidt E, Wehr B, Tabengwa EM, 
Reimer S, Bröcker EB, Zillikens D.  
Elevated expression and release 
of tissue-type, but not urokinase-
type, plasminogen activator after 
binding of autoantibodies to bullous 
pemphigoid antigen 180 in cultured 
human keratinocytes. Clinical 
and Experimental Immunology. 
2004;135:497-504
[58] Hofmann SC, Voith U, Schönau V, 
et al. Plasmin plays a role in the In vitro. 
Generation of the linear IgA Dermatosis 
antigen LADB97. Journal of Investigative 
Dermatology. 2009;129:1730-1739. DOI: 
10.1038/jid.2008.424
[59] Nishie W, Lamer S, Schlosser A, 
Licarete E, Franzke CW, Hofmann 
SC, et al. Ectodomain shedding generates 
Neoepitopes on collagen XVII, the major 
autoantigen for bullous pemphigoid. Journal 
of Immunology. 2010;185:4938-4947.  
DOI: 10.4049/jimmunol.1001524
[60] Forssmann U, Stoetzer C, Stephan M, 
Kruschinski C, Skripuletz T, Schade J,  
et al. Inhibition of CD26/dipeptidyl 
peptidase IV enhances CCL11/eotaxin-
mediated recruitment of eosinophils 
in vivo. Journal of Immunology. 
2008;181:1120-1127
[61] Filippatos TD, Athyros VG, 
Elisaf MS. The pharmacokinetic 
considerations and adverse effects 
of DPP-4 inhibitors [corrected]. 
Expert Opinion on Drug Metabolism 
& Toxicology. 2014;10:787-812. DOI: 
10.1517/17425255.2014.907274
[62] Ujiie H, Muramatsu K, Mushiroda T, 
Ozeki T, Miyoshi H, Iwata H, et al. HLA-
DQB1*03:01 as a biomarker for genetic 
susceptibility to bullous pemphigoid 
induced by DPP-4 inhibitors. The 
Journal of Investigative Dermatology. 
2018;138:1201-1204. DOI: 10.1016/j.
jid.2017.11.023
